Beyond HTA: Pricing Negotiations and Managed Entry Agreements across Europe

- United Kingdom: Beyond Patient Access Schemes - What is now negotiable? - Italy: Payment by results and managed entry agreements - France: CEPS agreements - Spain: the P&R system, negotiations with the DGCBSSNS, managed entry agreements, and Patient Access Schemes - Germany: AMNOG and the prospective cohort model; EU HTA and the 2027 price negotiationsThis seminar gives you a clear, comparative understanding of how innovative pricing and reimbursement agreements are structured and negotiated across the UK, Italy, France, Spain, and Germany. LernzieleThis seminar gives you a clear, comparative understanding of how innovative pricing and reimbursement agreements are structured and negotiated across the UK, Italy, France, Spain and Germany. You will learn to distinguish financial-based, performance-based, and mixed models and understand the regulatory logic behind each market.- The direct exchange with experienced experts from across Europe allows you to ask the questions that matter for your own projects.ZielgruppenThis seminar addresses professionals from the pharmaceutical and biotech industry working in market access, pricing and reimbursement, health economics and commercial strategy. It is equally relevant for those responsible for launch planning of innovative or high-cost therapies who want a comparative European perspective.